BBS-Bioactive Bone Substitutes Oyj

Equities

BONEH

FI4000260583

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Helsinki 11:01:41 2024-04-26 am EDT 5-day change 1st Jan Change
0.478 EUR -0.21% Intraday chart for BBS-Bioactive Bone Substitutes Oyj -0.42% -2.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bbs-Bioactive Bone Substitutes Oyj Announces the Cessation of Jari Kortesluoma as Member of the Management Team CI
Bbs-Bioactive Bone Substitutes Oyj Announces the Cessation of Jari Kortesluoma as CFO CI
Oy Jamerco Ltd. Terminates Its Service Contract with BBS-Bioactive Bone Substitutes Oyj CI
BBS-Bioactive Bone Substitutes Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BBS-Bioactive Bone Substitutes Obtains Financing for Working Capital MT
Bbs-Bioactive Bone Substitutes plc Appoints Kimmo Tyni as Product Director, effective January 15, 2024 CI
BBS-Bioactive Bone Substitutes Plc Announces Director Changes CI
BBS-Bioactive Bone Substitutes Closes EUR2 Million Rights Issue MT
BBS-Bioactive Bone Substitutes Closes EUR2 Million Rights Issue MT
BBS-Bioactive Bone Substitutes Secures Subscription Pledges from Two Investors for Rights Offering MT
BBS-Bioactive Updates Schedules of CE Marking Process for Bone Void Filler Product MT
BBS-Bioactive Bone Substitutes Plc Announces CEO Changes CI
Finland's BBS-Bioactive to Convert Notes MT
BBS-Bioactive Bone Substitutes Issues Shares without Consideration; Stock Drops 10% MT
BBS-Bioactive Bone Substitutes Oyj Reports Earnings Results for the Half Year Ended June 30, 2023 CI
BBS-Bioactive Bone Substitutes Oyj Reports Earnings Results for the Full Year Ended December 31, 2022 CI
BBS-Bioactive Bone Substitutes Oyj Provides Financial Guidance for 2023 CI
BBS-Bioactive Bone Substitutes Gets Approval to Delist from Swedish Bourse MT
BBS-Bioactive Bone Substitutes To Withdraw Nasdaq First North Growth Market Sweden Listing MT
Bbs-Bioactive Bone Substitutes plc Announces Appointment of Jari Kortesluoma as Member of the Management Team CI
Bbs-Bioactive Bone Substitutes Oyj Announces Appointment of Jari Kortesluoma as CFO CI
BBS-Bioactive Bone Substitutes CFO to Quit in September MT
BBS-Bioactive Bone Substitutes Oyj Announces Resignation of Liisa Hukka, CFO CI
BBS-Bioactive Bone Substitutes Oyj Reports Earnings Results for the Half Year Ended June 30, 2022 CI
BBS-Bioactive COO To Go On Leave Until October 2023 MT
Chart BBS-Bioactive Bone Substitutes Oyj
More charts
BBS-Bioactive Bone Substitutes Oyj (BBS) is a Finland-based company engaged in the medical equipment industry. The Company operates as a biotechnology company that develops and distributes medical device implants used in orthopedic surgery. Its products include ARTEBONE, an orthopedic bone substitute material made from reindeer bone protein matrix made using a propriety patented manufacturing process that can be used in various application areas, such as bone regeneration, healing of fractures, non-unions, bone defect, dental implantation, orthopedics, maxillofacial/dental surgery and osteoporotic fractures.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
1
Last Close Price
0.478 EUR
Average target price
0.5 EUR
Spread / Average Target
+4.60%
Consensus
  1. Stock Market
  2. Equities
  3. BONEH Stock
  4. News BBS-Bioactive Bone Substitutes Oyj
  5. BBS-Bioactive Bone Substitutes Obtains Financing for Working Capital